Contribution of hepatic ABCG5/G8 overexpression to sterol transport and atherosclerosis
INTRODUCTION
Sitosterolemia, also known as phytosterolemia (1-9) is a rare genetic disorder characterized by elevated plasma and tissue levels of plant, shellfish and animal sterols and the development of tendon and tuberous xanthomas, hemolytic episodes, arthritis and premature coronary artery disease. The ATP-binding cassette (ABC) halftransporters ABCG5 and ABCG8 (ABCG5/G8) have been recently identified as the genes defective in sitosterolemia (10) (11) (12) . The increased plasma and tissue levels of animal and plant sterols found in sitosterolemic patients has been attributed to enhanced absorption and decreased biliary excretion (1;2;2-4;6;8; [13] [14] [15] [16] . Unlike cholesterol, sitosterol accumulation does not inhibit HMGCoA reductase activity in human monocyte-derived macrophages (17) . The inadequate downregulation of HMGCoA reductase activity by plant sterols may promote foam cell formation and explain, in part, the increased risk of atherosclerosis in sitosterolemia (17) .
Several lines of evidence implicate ABCG5/G8 in intestinal and biliary sterol transport. First, ABCG5/G8 are expressed in the liver and small intestine and, to a lesser degree, in the colon (10;12;18-20) and gallbladder (21) and have been shown to traffic to the apical surface of polarized hepatocyte WifB cells as heterodimers (22) .
Second, both in vitro and in vivo studies have shown that ABCG5/G8 gene expression is modulated by transcription factors previously implicated in lipid and sterol metabolism. Agonists of LXR, a nuclear hormone receptor involved in sterol metabolism, enhance ABCG5/G8 gene expression in rat hepatoma cells (19) and feeding mice cholesterol-rich diets upregulates ABCG5/G8 gene expression in the liver and intestine of normal but not LXRα-deficient mice (10) . Deficiency of ABCG5 and ABCG8 in mice leads to increased intestinal cholesterol absorption and decreased gall bladder bile cholesterol concentration (23) , a phenotype similar to that of patients with sitosterolemia. Conversely, overexpression of human ABCG5/G8 raised the gallbladder cholesterol concentrations by more than 5-fold and reduced dietary sterol absorption by 50% in transgenic mice (24) . Finally, recent studies in mice and rats have demonstrated an association between ABCG5 and ABCG8 gene expression and changes in biliary cholesterol secretion and intestinal cholesterol absorption (25) (26) (27) .
Thus, ABCG5/G8 are transporters that play a major role in the excretion of cholesterol and other sterols from the body.
Here we report the generation of transgenic mice that selectively overexpress hABCG5/G8 in the liver of C57Bl/6, apoE-KO, and LDLr-KO mice. We describe the contribution of liver ABCG5/G8 to hepatobiliary sterol transport and evaluate the effects of hepatic overexpression of these transporters on the development of atherosclerotic lesions. Our studies directly demonstrate a role for liver ABCG5/G8 in facilitating sterol secretion into bile and in reducing the plasma concentrations of potentially proatherogenic plant sterols in plasma. However, hepatic overexpression of ABCG5/G8 did not reduce fractional intestinal cholesterol absorption nor facilitate the elimination of cholesterol from liver G5/G8-Tg over that of control mice. Hence, despite increased hepatobiliary sterol secretion, overexpression of ABCG5/G8 in the liver did not alter hepatic cholesterol concentrations or induce compensatory changes in liver enzymes and in hepatic receptors that might lead to antiatherogenic changes in the plasma lipoprotein profile and decrease aortic atherosclerosis in C57Bl/6, apoE-KO and LDLr-KO mice. These findings identify separate functions for hepatic and intestinal ABCG5/G8, and suggest that increased expression of intestinal as well as hepatic ABCG5/G8 may be required to significantly increase the elimination of body cholesterol and modulate atherogenic risk.
EXPERIMENTAL PROCEDURES
Generation of ABCG5/G8 Transgenic Mice─A fully characterized and sequenced 140-kb BAC clone (BAC 26313; Incyte Genomics, Palo Alto, CA) encoding the complete ABCG5 and ABCG8 proteins (28) was used to generate transgenic mice in the C57Bl/6 background as described (29) . Integration of the hABCG5/G8 genes was determined by dot blot hybridization analysis of genomic mouse tail DNA using full length hABCG5/G8 cDNA probes and confirmed by PCR using human-specific ABCG5/G8 primers (sequences available upon request). Several different mouse lines expressing hABCG5/G8 were identified and expanded for further studies. To generate apoE-KO or LDLR-KO mice overexpressing hABCG5/G8, transgenic mice were crossed with apoE- Diets─Control and transgenic mice (2-5 months of age) were maintained on the NIH-31 rodent diet (Harlan Teklad, Madison WI), designated as the regular chow diet (RCD; 0.025% cholesterol, 0.05% sitosterol, 0.015% campesterol and 0.007% stigmasterol), or a 4% cholesterol diet (designated 4%C; 3.9% cholesterol, 0.04% sitosterol, 0.016% campesterol, and 0.009% stigmasterol) for a period of 10-12 weeks prior to analyses.
To induce the formation of aortic lesions, C57Bl/6 control and transgenic mice were placed on the high-fat, high-cholesterol/cholate diet as described (30;31) and LDLr-KO mice were placed on a Western diet (0.2% cholesterol, 21% fat, <0.003%sitosterol, campesterol and stigmasterol). All diets were analyzed by Woodson-Tenent Laboratories (Memphis, TN) to confirm their sterol content. Daily food intake was measured in a representative group of 4 mice for each study group. Analyses of Plasma Lipids─Plasma was obtained after a 4-hour fast and lipid levels were determined as previously described (29;32) . HDL-cholesterol (HDL-C) was determined as the cholesterol remaining in the plasma after precipitation of the apoBcontaining lipoproteins with heparin-calcium (Ciba-Corning, OH) or dextran-sulfate (Bayer Corp. Tarrytown, NY). Plasma levels of apolipoproteins were quantified by Western blot analysis followed by densitometric scanning as described (29;32) .
RNA Isolation and Northern Blot Analysis─Total
Western Blot Analysis─Mouse liver proteins purified as previously described (34) were electrophoresed on 4-12% Bis-Tris acrylamide gels (Invitrogen), transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA) and incubated with primary antibodies against human LDLr (RDI, Flanders, NJ), mouse SR-BI (Novus Biologicals, Littleton, CO) and mouse anti-LRP (a generous gift from Dr. Dudley K. Strickland) (33).
The secondary antibody was a donkey anti-rabbit or goat anti-mouse antibody conjugated to horseradish peroxidase (Amersham, Piscataway, NJ). Proteins were detected by chemiluminescence (33) .
Fast Protein Liquid Chromatography and Native Agarose Gel
Electrophoresis─Plasma lipoproteins were analyzed by native agarose gel electrophoresis and FPLC (50ul of plasma pooled from 4 mice) as previously described (29;32;33 for analysis of hepatic and fecal total neutral sterols using an enzymatic assay as described (41) .
Analysis of Aortic Lesions─The heart and attached section of ascending aorta were dissected en bloc and prepared as previously described (30) . Three mm sections of the aortic root and ascending aorta were stained with oil-red-O for neutral lipids and hematoxylin for nucleic tissue. Five sections per animal were evaluated to determine the mean cross-sectional area of lesions for each animal (30) .
Statistical Analysis─All data are expressed as means+/-SEM. Statistically significant differences between control and transgenic mice were assessed by Student's t-test and defined as a two-tailed probability of less than 0.05. Non-parametric data was analyzed by the Mann-Whitney test (Instat Software, Graphpad, Inc., San Diego, CA).
RESULTS

Characterization of Transgenic Mice with Liver-Specific hABCG5/G8
Overexpression on a Low Sterol Diet
Liver-Specific Overexpression of Human ABCG5/G8 Does Not Alter Hepatobiliary Sterol Secretion and Intestinal Cholesterol Absorption on a Low Sterol Diet─ABCG5
and ABCG8 expressed in liver and intestine have important roles in biliary and intestinal sterol transport (10-12;23) but the independent contribution of hepatic ABCG5/ABCG8
has not yet been investigated. We generated a transgenic mouse line (Tg) with 63 copies of the human ABCG5 and ABCG8 genes under control of their native promoter by injecting a BAC construct containing the entire hABCG5/G8 locus (28) into C57Bl/6 mice. Northern analysis using probes that detect both mouse and human ABCG5/G8 demonstrated that ABCG5 and ABCG8 mRNA was increased in the liver (~2-3-fold) but not small intestine of liver G5/G8-Tg mice compared to nontransgenic control mice ( Fig.   1A ; left panels). Northern analysis using human-specific probes (hG5 and hG8; Fig. 1A ;
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http://www.jbc.org/ Downloaded from middle panels) confirmed the presence of human ABCG5 and ABCG8 transcripts in the liver, but not small intestine, of liver G5/G8-Tg mice. Human ABCG5/G8 overexpression did not alter mABCG5 or mABCG8 mRNA levels in the liver or intestine of liver G5/G8-Tg mice ( Fig. 1A ; right panels). These findings were further confirmed by real time RT-PCR using human-or mouse-specific primers (data not shown). The liverspecific pattern of hABCG5/G8 gene expression in liver G5/G8-Tg mice allowed us to investigate the contribution of liver ABCG5 and ABCG8 to sterol transport and atherosclerosis. (Table IA) (Table IA) . Fecal neutral sterol excretion, which on a low sterol diet (0.025% cholesterol, 0.072% plant sterols) consists mostly of dietary plant sterols, was unchanged in liver G5/G8-Tg (n=9; 2.96+/-0.14 mg fecal sterol/day) vs control (n=11; 2.91+/-0.27-GC mg fecal sterol/day) mice. Similarly, no difference in the daily fecal cholesterol excretion was evident between Tg (n=9; n=6, 1.17+/-0.06 mg fecal cholesterol/day) and control (n=11; 1.08+/-0.21-GC mg fecal cholesterol/day) mice. Not surprisingly, no differences in either the hepatic cholesterol concentrations (Table IA) Thus, on the low sterol diet the increased levels of human ABCG5/G8 expression did not alter the biliary sterol excretion or intestinal cholesterol absorption already mediated by the endogenous mouse ABCG5 and ABCG8 transporters in our liver G5/G8-Tg mice.
Characterization of Transgenic Mice with Liver-Specific hABCG5/G8
Overexpression on a 4% Cholesterol Diet
Increased Dietary Cholesterol Enhances Expression of ABCG5/G8 and Raises
Hepatic and Plasma Cholesterol Levels in both Liver G5/G8-Tg and Control Mice─We
first analyzed the general effects of the cholesterol-rich diet on both control and liver G5/G8-Tg mice. Northern analysis using probes that recognize both mouse and human ABCG5/G8 ( Fig. 2A ) demonstrated that, compared to the RCD, the 4%C diet increased expression of ABCG5 and ABCG8 in the liver and intestine of both liver G5/G8-Tg and control mice (by approximately 2 fold). Further studies using mouse-and humanspecific probes showed that the cholesterol-rich diet enhanced hepatic expression of mouse ABCG5 and ABCG8 in both Tg and control mice and of human ABCG5/G8 in Tg mice. As on the RCD, human ABCG5/G8 mRNA was increased in liver but not intestine of liver G5/G8-Tg mice compared to control mice ( Fig. 2A ).
Compared to the low sterol diet (RCD), the 4%C diet raised the fasting plasma levels and increased hepatic cholesterol content (~ 3 fold; p<0.0001; Table IA vs IB) of both liver G5/G8-Tg and control study groups. Increased dietary cholesterol also significantly raised the biliary sterol secretion rate of control (1.5-fold) and liver G5/G8-Tg (2.9-fold) mice compared to similar mice on a RCD (Table IA vs and secretion rates by 1.9-fold (6.73+/-0.31 vs 3.63+/-0.07 umol/hr/kgBW in liver G5/G8-Tg mice compared to nontransgenic controls (Table IB) On the 4%C diet, compared to the low sterol diet, the percent intestinal cholesterol absorption was reduced in both control (n=13; 25.82+/-1.49%) and liver G5/G8-Tg (n=13; 26.43+/1.72%) mice (Table IB) . This finding is consistent with previous reports demonstrating that when the amount of dietary cholesterol is increased fractional intestinal cholesterol absorption is decreased (45) . As on the RCD no significant difference in intestinal cholesterol absorption was evident between the two mouse study groups. These combined findings demonstrate that selective hepatic overexpression of ABCG5/G8 enhances biliary sterol secretion but does not alter intestinal cholesterol absorption in mice. Since feeding a cholesterol-rich diet can alter the fractional cholesterol absorption measured by the dual isotope method we also determined intestinal cholesterol absorption using the cholesterol balance approach (45) . The mg amounts of cholesterol absorbed daily were calculated by subtracting the mg of cholesterol excreted in the feces each day from the total amount of cholesterol present daily in the intestine of Tg and control mice ( mg/d increase in the daily mg amount of cholesterol absorbed from the gut and transported via chylomicrons back to the liver in liver G5/G8-Tg. Thus, although hepatic overexpression of ABCG5/G8 enhanced hepatobiliary sterol secretion (by 1.9 fold) on the 4%C diet, it did not alter the cholesterol balance across the liver nor increase removal of body cholesterol from liver G5/G8-Tg vs control mice. Consequently, the increased biliary sterol secretion observed in liver G5/G8-Tg mice was not associated with reductions in the hepatic cholesterol content (Table IB) or compensatory alterations in liver expression of the LDL receptor, ABCA1, ABCG1, SR-BI, HMGCoA reductase and 7-alpha hydroxylase compared to control mice (data not shown).
Hepatic Overexpression of hABCG5/G8 Alters Plant Sterol Concentrations in
Plasma on the 4%C Diet─Analysis of the plasma lipid profile revealed no differences between transgenic and control mice on the 4%C diet (Fig. 2B ). Hepatic overexpression of ABCG5/G8 did, however, significantly reduce the plasma campesterol levels (by ~35%) and campesterol/cholesterol ratio (in liver G5/G8-Tg mice compared to controls) (Fig. 2C) indicating that overexpression of ABCG5 and ABCG8 only in liver is sufficient to decrease the accumulation of plant sterols in plasma.
Hepatic Overexpression Of hABCG5/G8 Does Not Alter Aortic Atherosclerosis in
Transgenic C57Bl/6 Mice on a HF-HC Diet─To investigate the effect of ABCG5 and ABCG8 overexpression on aortic lesion formation in C57Bl/6 mice, we placed liver G5/G8-Tg and control mice on a high cholesterol, cholate-containing (HF-HC) diet for 12 weeks (30;31). This cholate-enriched diet is necessary to induce lesion formation in C57Bl/6 mice. As expected, the plasma TC, PL, CE, and FC plasma levels were increased in all 3 mouse study groups (data not shown). However, no significant differences in the plasma lipid profiles of liver G5/G8-Tg compared to control nontransgenic mice were evident after 12 weeks of the HCC diet (data not shown induce lesion formation; apoE-KO mice were crossed with liver G5/G8-Tg mice to generate liver G5/G8-Tg x E-KO mice. As observed in Tg mice on a C57Bl/6 background ( Fig. 1A) , both human transgenes were primarily expressed in the liver but not the small intestine of liver G5/G8-Tg x E-KO mice (Fig. 3A) and expression of mouse ABCG5 and ABCG8 was similar between liver G5/G8-Tg x E-KO and E-KO mice in both the liver and the intestine (Fig. 3A) .
The plasma cholesterol, PL, FC, CE and non-HDL cholesterol (Fig. 3B vs Fig. 1B) as well as the hepatic cholesterol content (Table IC vs. Table IA ) of E-KO and liver G5/G8-Tg x E-KO mice were increased compared to C57Bl/6 and Tg mice on a RCD.
Furthermore, both E-KO and liver G5/G8-Tg x E-KO Tg mice had markedly increased biliary sterol secretion rates (3-4 fold) compared to the analogous C57Bl/6 mice (Table   IC vs Table IA) . p=0.03) in liver G5/G8-Tg x E-KO compared to E-KO mice (Table IC) . As on the 4%C diet, enhanced hepatobiliary sterol secretion in liver G5/G8-Tg x E-KO vs E-KO mice occurred in the context of increased hepatic cholesterol content (Table IC) , compared to liver G5/G8-Tg and C57Bl/6 mice on RCD (Table IA) , which increases the amount of cholesterol substrate available for ABCG5/G8 transport. As before, the biliary phospholipid and bile acid secretion rates were similar between E-KO and liver G5/G8-Tg x E-KO mice (data not shown). Fractional intestinal cholesterol absorption was not decreased in liver G5/G8-Tg x E-KO vs control E-KO mice; in fact, a trend for increased cholesterol absorption that did not reach statistical significance (p<0.09) was evident in liver G5/G8-Tg (n=12, 75.87+/-2.23%) vs control E-KO (n=22; 64.73+/-3.53%) mice on the RCD (Table IIC) . These data again demonstrate that selective hepatic overexpression of ABCG5/G8 enhances biliary sterol but not intestinal sterol transport. Consistently, the increased biliary sterol secretion in liver G5/G8-Tg x E-KO mice was not associated with changes in either hepatic cholesterol concentrations (Table   IIC) , liver cholesterol synthesis (E-KO, n=4; 347.57+/-82.35 vs liver G5/G8 Tg x E-KO, n=4; 308.94+/-79.30 nmole/hr/g; p>0.05), or changes in liver expression of the LDL receptor, ABCA1, ABCG1, SR-BI, HMGCoA reductase and 7-alpha hydroxylase compared to E-KO mice (data not shown). Furthermore, no significant differences in the mean fasting plasma concentrations of TC, TG, PL, CE, HDL-C, apoA-I, and apoB or in the plasma lipoproteins ( Fig. 3B and 3C ) were evident between E-KO and liver G5/G8-Tg x E-KO mice. Hepatic overexpression of ABCG5/G8 did, however, reduce the campesterol levels (by ~ 25%) and campesterol/cholesterol ratio (by ~20%) in plasma of liver G5/G8-Tg x E-KO compared to E-KO mice (Fig. 3D ).
To evaluate whether the increased biliary sterol secretion induced by hepatic ABCG5/G8 overexpression altered atherosclerosis, we analyzed the proximal aortas of 3 and 4 month old female and 4-month old male liver G5/G8-Tg x E-KO and apoE-KO mice fed a RCD (Fig. 3E) . As anticipated by the absence of changes in the plasma lipid profile, no differences in proximal aortic lesions were detected between the aortas of 3 month old and 4 month old female or between aortas of 4 month old male liver G5/G8-by guest on October 1, 2017
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Tg x E-KO and E-KO mice.
Hepatic Overexpression of hABCG5/G8 Enhances Hepatobiliary Sterol Excretion, but Does Not Alter the Plasma Lipoproteins or Alter Aortic Atherosclerosis In
LDLr-KO Mice Fed a Western Diet
Generation of LDLr-KO x hABCG5/G8-Tg Mice─We also investigated the effects of hepatic ABCG5 and ABCG8 overexpression on sterol transport and aortic atherosclerosis in a second atherosusceptible mouse model by crossing LDLr-KO mice with liver G5/G8-Tg mice. As in C57Bl/6 and E-KO mice, both human transgenes were primarily expressed in the liver but not small intestine of liver G5/G8 LDLr-KO x Tg mice ( Fig. 4A ) and expression of mouse ABCG5 and ABCG8 was similar between both study groups in both liver and intestine (Fig 4A) .
On the Western diet the plasma cholesterol levels ( Fig. 4B vs Fig. 1B ) and hepatic cholesterol content (Table ID vs. Table IA) of LDLr-KO and liver G5/G8 LDLr-KO x Tg mice were increased compared to C57Bl/6 mice on a RCD. Both LDLr-KO and liver G5/G8 LDLr-KO x Tg mice had markedly increased biliary sterol (3-6 fold) secretion rates compared to the analogous C57Bl/6 mice (Table ID vs Table IA) .
Hepatic Overexpression of hABCG5/G8 in LDLr-KO Mice Enhances Biliary Sterol Secretion but not Aortic Atherosclerosis in Liver G5/G8 Tg x LDLr-KO
Mice─Overexpression of ABCG5 and ABCG8 in liver increased the biliary sterol secretion rates in liver G5/G8-Tg x LDLr-KO mice compared to LDLr-KO mice (13.75+/-1.18 vs. 7.94+/-0.94 umol/hr/kgBW;1.7-fold, p<0.002) ( Table ID) . As before, the biliary phospholipid and bile acid secretion rates were similar between LDLr-KO and LDLr-KO x Tg mice (data not shown) and no significant difference (p=0.09; all) in fractional intestinal cholesterol absorption was evident between LDLr-KO (n=5, 46.39+/-2.09%) and liver G5/G8 Tg x LDLr-KO mice (n=8, 57.7+/-3.53%) (Table ID) . (Table IID) These combined data indicate that, despite a 1.7-fold increase in biliary cholesterol secretion and an 18% increase in intestinal cholesterol, in the absence of changes in fractional intestinal cholesterol absorption hepatic overexpression of ABCG5/G8 did not significantly alter the cholesterol balance acroos the liver nor increase the daily excretion of fecal cholesterol liver G5/G8-Tg x LDLr-KO vs control LDLr-KO mice.
Consistently, the increased biliary sterol excretion in liver G5/G8-Tg x LDLr-KO mice was not associated with either decreased hepatic cholesterol concentrations (Table IIC) , Fig. 4B and 4C ) between LDLr-KO and liver G5/G8-Tg x LDLr-KO mice. Although on the Western diet no differences in the plasma concentrations of campesterol, sitosterol as well as plant sterol/cholesterol ratios were evident (data not shown), hepatic overexpression of ABCG5/G8 reduced the campesterol concentrations (by 30%) as well as the campesterol/cholesterol ratio (by 31%) in plasma of liver G5/G8-Tg x LDLr-KO compared to LDLr-KO mice on the RCD (Fig. 4D ).
To evaluate whether the increased biliary sterol excretion induced by ABCG5/G8 overexpression altered atherosclerosis, we analyzed the proximal aortas of 10-and 13-week-old male and female LDLr-KO and liver G5/G8-Tg x LDLr-KO mice fed a Western diet (Fig. 4E) . No difference in proximal aortic lesions were evident in either female or male liver G5/G8-Tg x LDLr-KO compared to LDLr-KO mice placed on a Western diet for either 10 or 13 weeks (Fig. 4E ).
DISCUSSION
While previous work has demonstrated that ABCG5 and ABCG8 are ABC halftransporters expressed primarily in liver and intestine that function to transport sterols Consequently, hepatic ABCG5/G8 overexpression did not protect against the development of aortic lesions in three independent mouse models of atherosclerosis.
Several lines of evidence demonstrate that the hABCG5 and hABCG8 transgenes were overexpressed and functional in liver. ABCG5/G8 mRNA levels were increased by approximatety 2-3 fold in liver of Tg mice in all study groups, compared to control nontransgenic mice. Secretion of sterols into bile was increased in liver G5/G8-Tg mice (compared to control nontransgenic mice) on the 4%C diet, for liver G5/G8-Tg x E-KO mice on a RCD, and for liver G5/G8-Tg x LDLR-KO mice on a Western diet. Each of these conditions imposed a significant sterol load upon the mouse liver. Hepatic overexpression of ABCG5/G8 also functioned to decrease plant sterol concentrations and plant sterol/cholesterol ratios in plasma of Tg mice on these diets compared to control nontransgenic mice in the same study group. Interestingly, when the hepatic sterol load was normal (C57Bl/6 mice on a RCD), the biliary sterol secretion rates for liver G5/G8-Tg and nontransgenic control mice were similar. These data indicate efficient processing of normal quantities of hepatic sterols by the endogenous mouse transporters and suggest that in addition to changes in ABCG5/G8 gene expression, the amount of hepatic sterols available for transport may be important for ABCG5/G8
function. In all studies, control and liver G5/G8-Tg mice had similar biliary bile acid and phospholipid secretion rates, indicating that hepatic ABCG5/G8 is not involved in transport of these lipids. Altogether, these studies demonstrate that liver ABCG5/G8 function to decrease excess levels of hepatic cholesterol and plant sterols, but not bile acids or phospholipids.
We note that the increase in biliary sterol concentration due to hepatic ABCG5/G8 overexpression in our transgenic mice (1.5-2 fold) was less than that observed for the human ABCG5/G8 transgenic mice generated by Yu et al. (5-fold) (24) , which express hABCG5/G8 in liver and intestine. These differences are likely due to different by guest on October 1, 2017
http://www.jbc.org/ Downloaded from ABCG5/G8 expression levels resulting from separate integration sites of the transgenes into the genome in these two independently generated ABCG5/G8 transgenic mouse lines. In addition, there are methodological differences between the two studies. We measured biliary sterol concentrations by the bile cannulation method which also permits calculation of daily hepatobiliary sterol secretion rates, whereas Yu et al.
measured sterol concentrations in gall bladder bile. A major drawback to the latter method is that changes in gallbladder contractility and secretion or resorption of biliary components can lead to fluctuations in concentrations of gall bladder bile lipids. This is especially relevant for studies involving ABCG5/G8 since both half-transporters are expressed in the gall bladder (21) . For these reasons, the bile cannulation method leads to more accurate and reproducible measurements, while also permitting direct assessment of daily biliary sterol secretion rates necessary for analysis of cholesterol appears to be due to the intestinal overexpression of ABCG5/G8, as reported (24) .
Increased hepatic expression of both half-transporters, significantly reduced the plasma concentrations of plant sterols, especially campesterol, and altered the plasma campesterol/cholesterol ratios in liver G5/G8-Tg mice. These findings suggest that there is a mechanism for selective removal of plant sterols from plasma by hepatic ABCG5/G8. Hepatic ABCG5/G8 could enhance the secretion of hepatic cholesterol and plant sterols into bile with equal affinity; depleted hepatic cholesterol pools may then be replenished by de novo cholesterol synthesis via HMGCoA reductase. Since this mechanism would replace lost cholesterol but not lost plant sterols, the plant sterol/cholesterol ratio in plasma would ultimately decrease. However, in our studies, the reduction in plasma plant sterols in liver G5/G8-Tg vs control mice persisted even when cholesterol levels in liver and plasma were high, and thus when de novo This combined data demonstrate that despite significantly enhancing (by 1.5-2 fold) the output of liver cholesterol via the bile, increasing ABCG5/G8 expression only in liver and not intestine failed to induce a net loss of hepatic cholesterol in liver G5/G8-Tg mice and suggest that hepatic overexpression of ABCG5/G8 will not protect against the development of atherosclerotic lesions. Indeed this is what we observed in three mouse models: C57Bl/6 mice on a CCB/cholate diet; apoE-KO mice on a RCD, and LDLr-KO mice on a Western diet.
Analysis of changes in the cholesterol balance across the liver induced by hepatic ABCG5/G8 overexpression in our liver G5/G8-Tg mice provides insight into these findings. Figure 5 summarizes the sterol transport of E-KO vs liver G5/G8-Tg x E-KO mice (left panel) and of LDLr-KO vs liver G5/G8-Tg x LDLr-KO mice (right panel).
Overexpression of ABCG5/G8 in liver significantly enhanced biliary cholesterol secretion in E-KO (by 1.4-fold) and LDLr-KO (by 1.7-fold) mice. Consequently, the amount of intestinal cholesterol available for absorption was also increased in liver G5/G8-Tg X E-KO vs E-KO mice (by 1.3-fold) and liver G5/G8-Tg x LDLr-KO vs LDLr-KO (by 1.2-fold) mice. However, since hepatic overexpression of ABCG5/G8 did not reduce the fractional intestinal cholesterol absorption in these two animal models, the daily amount of cholesterol absorbed from the intestine was also greater in liver G5/G8-Tg x E-KO vs E-KO (by 1.5-fold) and in liver G5/G8-Tg x LDLr-KO vs LDLr-KO (by 1.5-fold). Thus, the increased hepatic cholesterol output via the biliary system in both liver G5/G8-Tg x E-KO and liver G5/G8-Tg x LDLr-KO mice was offset by greater input of cholesterol to the liver resulting from absorption and transport of intestinal cholesterol via chylomicrons. Consequently, hepatic overexpression of ABCG5/G8 did not alter fecal cholesterol excretion in C57Bl/6, apoE-KO and LDLr-KO mice. No significant changes in bile acid fecal excretion are anticipated in these mice since biliary bile acid secretion was similar between control and liver G5/G8-Tg mice in all genetic backgrounds and previous studies have shown that bile acid pool size is not altered by ABCG5/G8 overexpression (24) . Thus, hepatic overexpression of ABCG5/G8 only in liver did not alter hepatic cholesterol balance nor enhance the elimination of cholesterol from the body in liver G5/G8-Tg mice vs control mice.
Our combined results demonstrate that hepatic ABCG5/G8 overexpression functions to increase cholesterol and plant sterol secretion into bile and serves as an alternative Northern blot analysis of total RNA isolated from liver and small intestine of E-KO and liver G5/G8-Tg x E-KO mice using probes that detect i) human transporters (hG5 and G8; top two panels) and ii) mouse transporters (mG5 and G8; panels 3 and 4 from top).
Panel B. Fasting plasma lipids, lipoproteins and apolipoproteins (inset) of plasma from 3-month-old female E-KO and liver G5/G8-Tg x E-KO mice (n=8-16, each group).
Panel C. FPLC analysis of pooled plasma (n=5, each group) from 3-month-old E-KO and liver G5/G8-Tg x E-KO mice. Panel D. Plasma cholesterol, campesterol and sitosterol concentrations and plant sterol/cholesterol ratios in 3-month-old female E-KO (white bars) and liver G5/G8-Tg x E-KO (black bar) mice (n=4-6, each group). Panel E.
Mean proximal aortic lesion area in 3-month-old female, 4-month-old female and 4-month-old male E-KO and liver G5/G8-Tg x E-KO mice on a RCD. Northern blot analysis of total RNA isolated from liver and small intestine of LDLr-KO (L-KO) and liver G5/G8-Tg x LDLr-KO (L-KO x Tg) mice using probes that detect i) human transporters (hG5 and G8; top two panels) and ii) mouse transporters (mG5 and G8; 
